An immunological comparison of third companion in advanced drug-naive HIV-infected patients

Giuliano Rizzardini, Daria Trabattoni, Amedeo Capetti, Eleonora Castelletti, Marco Migliorino, Ruggero Panebianco, Michela Pacei, Tiziana Quirino, Mario Clerici

Research output: Contribution to journalArticlepeer-review


An immunological comparison of three different third companions (abacavir [ABC], efavirenz [EFV], ritonavir-boosted indinavir [IDVr]) on a backbone of either zidovudine plus didanosine (AZT/ddl) or zidovudine plus lamivudine (AZT/3TC) was performed in 76 HIV-infected, advanced-naive patients. Baseline median CD4 count and viremia were 217/ μL and 238,301 copies/mL, respectively. Immunologic parameters were measured at baseline and after months of therapy. By the end of the study, 36 patients (mostly in the protease inhibitor [PI]-containing arms) had dropped out of the study; 22/36 cases of drop out were due to tolerability issues. All regimens resulted in increases in CD4 counts, with the most solid changes seen in patients using ABC as a third companion. Median HIV plasma viremia at month 12 was

Original languageEnglish
Pages (from-to)221-228
Number of pages8
JournalHIV Clinical Trials
Issue number5
Publication statusPublished - Sep 2006


  • Advance-naïve patients
  • Antiviral therapy
  • HIV
  • Immune modulation
  • Immunology
  • Third companion

ASJC Scopus subject areas

  • Virology
  • Immunology


Dive into the research topics of 'An immunological comparison of third companion in advanced drug-naive HIV-infected patients'. Together they form a unique fingerprint.

Cite this